Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia

JAMA

Volumn 275, Issue 2, 1996, Pages 128-133

  Bakker Arkema, Rebecca G ^a   Davidson, Michael H ^b   Goldstein, Robert J ⁱ   Davignon, Jean ^c   Isaacsohn, Jonathan L ^d   Weiss, Stuart R ^e   Keilson, Leonard M ^f   Brown, W Virgil ^g   Miller, Valery T ^h   Shurzinske, Linda J ^a   Black, Donald M ^a  

^a PFIZER INC   (United States)

^b RADIANT RESEARCH   (United States)

^c CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^d CHRIST HOSPITAL   (United States)

^e S Diego Endocr and Medical Clinic   (United States)

^f Clinical Researcn Management   (United States)

^g EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

ⁱ Parke Davis Pharmaceutical Research ^*

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY RISK; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ENZYME INHIBITION; FEMALE; HUMAN; HYPERTRIGLYCERIDEMIA; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 9044230921     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.275.2.128     Document Type: Article

References (24)

1. Austin MA. Plasma triglyceride and coronary heart disease. Arterioscler Thromb Vasc Biol. 1991; 11:2-14.
2. Hulley SB, Rosenman RH, Bawol RD, Brand RJ. Epidemiology as a guide to clinical decisions: the association between triglyceride and coronary heart disease. N Engl J Med. 1980;302:1383-1389.
3. Jacobs DR Jr, Barrett-Connor E. Retest reliability of plasma cholesterol and triglyceride: the Lipids Research Clinics prevalence study. Am J Epidemiol. 1982;116:878-885.
4. Mahley RW, Rall SC Jr. Type III hyperlipoproteinemia (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic Basis of Inherited Disease. 6th ed. New York, NY: McGraw-Hill Book Co: 1989:1195-1213.
5. Grundy SM, Vega GL. Two different views of the relationship of hypertriglyceridemia to coronary heart disease. Arch Intern Med. 1992;152:28-34.
6. Genest JJ Jr, Martin-Munley SS, McNamara JR, et al. Prevalence of familial lipoprotein disorders in patients with premature coronary artery disease. Circulation. 1992;85:2025-2033.
7. National Institutes of Health Consensus Development Panel. Triglyceride, high-density lipoprotein, and coronary heart disease. Consensus Statement. 1992;10:1-28.
8. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993;269:3015-3023.
9. European Atherosclerosis Society. Prevention of coronary heart disease: scientific background and new clinical guidelines. Nutr Metab Cardiovasc Dis. 1992;2:113-156.
10. McKenney JM, Proctor JD, Harris S, Chinchili VM. A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients. JAMA. 1994;271:672-677.
11. East C, Bilheimer DW, Grundy SM. Combination drug therapy for familial combined hyperlipidemia. Ann Intern Med. 1988;109:25-32.
12. Krause BR, Bousley R, Kieft K, Stanfield R, Newton RS. CI-981 is superior to lovastatin for lowering plasma triglycerides in experimental animals. FASEB J. 1993;7:A567. Abstract 3289
13. Nawrocki JW, Weiss SR, Davidson MH, et al. Reduction of LDL-cholesterol by 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol. 1995;15:678-682.
14. Remmell PS. Gorder DD, Hall Y, Tillotson JL. Assessing dietary adherence in the Multiple Risk Factor Intervention Trial (MRFIT), I: use of a dietary monitoring tool. J Am Diet Assoc. 1980;76: 351-356.
15. Feskanich D, Buzzard IM, Welch BT, et al. Comparison of a computerized and manual method of food coding for nutrient intake studies. J Am Diet Assoc. 1988;88:1263-1267.
16. Manual of laboratory operations lipid research clinics program. In: Hainline A, Karon J, Lippel K, eds. Lipid and Lipoprotein Analysis. 2nd ed. Bethesda, Md: National Heart, Lung, and Blood Institute, National Institutes of Health; 1982:5.
17. 2+ precipitation procedure for quantitation of high density-lipoprotein cholesterol. Clin Chem. 1982;28:1379-1388.
18. Parra HJ, Mezdour H, Ghalim N, Bard JM, Fruchart JC. Differential electroimmunoassay of human LpA-I lipoprotein particles on ready-to-use plates. Clin Chem. 1990;36:1421-1425.
19. Schonfeld G, Chen J, McDonald WF, Jeng I. Apolipoprotein A-II content of human plasma high density lipoproteins measured by radioimmunoassay. J Lipid Res. 1977;18:645-655.
20. Ma PTS, Gil G, Sudof TC, Bilheimer DW, Goldstern JL, Brown MS. Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits. Proc Natl Acad Sci U S A. 1986;83:8370-8374.
21. Grundy SM. HMG-CoA reductase inhibitors: clinical applications and therapeutic potential. In: Rifkind BM, ed. Drug Treatment of Hyperlipidemia. New York, NY: Mercel Dekker Inc; 1991: 139-167.
22. Goh EH, Heimer M. Effects of free fatty acids on activity of hepatic microsomal 3-hydroxy-3-methyglutaryl coenzyme A reductase and on secretion of triglyceride and cholesterol by liver. J Biol Chem. 1977;252:2822-2826.
23. Kasim SE, LeBoeuf RC, Khilnani S, Tallapaka L, Dayananda D, Jen KL. Mechanisms of triglyceride-lowering effect of HMG-CoA reductase inhibitor in a hypertriglyceridemic model, the Zucker obese rat. J Lipid Res. 1992;33:1-7.
24. Marais AD, Firth JC, Batemon M, Jones J, Mountney J, Marten C. Atorvastatin is a powerful and safe agent for lowering plasma cholesterol concentration in heterozygous familial hypercholesterolaemia. Atherosclerosis, 1994;109(special issue);316. Abstract 226.